Table 4.
New agents that are currently investigated in follicular lymphoma
| Target | Type | Agents |
| Proteasome | Proteasome inhibitor | Bortezomib, carfilzomib, NPI 00-52 |
| CD 19 | MoAb | Blinatumomab |
| CD20 | MoAb | Ofatumumab, IMMU-06, ocrelizumab, GA101 |
| CD22 | MoAb | Epratuzumab, inotuzumab, ozogamicin |
| CD40 | MoAb | SGN-40 (dacetuzumab) |
| CD80 | MoAb | Galiximab |
| DNA | Cytotoxic | Bendamustine |
| Unknown | IMiD | Lenalidomide |
| HDAC | HDAC inhibitor | MGCD0103, vorinostat, panobinostat, belinostat, romidepsin |
| Syk | Syk inhibitor | Fostamatinib |
| m-TOR | m-TOR inhibitor | Temsirolimus, everolimus |
| Bcl-2 family | Anti-apoptosis | Oblimersen sodium, obatoclax mesylate, ABT-263 |
MoAb: Monoclonal antibody; HDAC: Hystone deacetylase; IMiD: Immunomodulatory derivatives